Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage)
Study Details
Study Description
Brief Summary
There are about 240 million chronic hepatitis B virus (HBV) infected people in the world, and about 2%-5% of compensated cirrhosis patients progress to decompensated cirrhosis patients every year. Studies have shown that the 5-year survival rate of decompensated cirrhosis is only 14-35%, and the quality of life and prognosis of patients are poor. Reversing or delaying the process of cirrhosis and reducing the development of compensated cirrhosis to decompensated cirrhosis is one of the effective methods for liver disease treatment. MSCs are mainly derived from bone marrow, but bone marrow mesenchymal stem cells have some shortcomings, such as cumbersome sampling, and the proliferation and differentiation ability of bone marrow mesenchymal stem cells decrease obviously with the age of donors, which is not conducive to cell therapy. Umbilical cord has many advantages, such as wide source, convenient collection, small immune rejection, and small ethical controversy, which makes it a hot spot in stem cell research and has a wider prospect in cell therapy. This clinical study will explore the efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of hepatitis B virus-infected patients with compensated cirrhosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
There are about 1.7 billion people with different types of chronic liver diseases in the world, of which about 240 million are infected with chronic hepatitis B virus (HBV), and about 15%-40% of chronic hepatitis B can develop into liver cirrhosis and die of liver hardness every year There are hundreds of thousands of patients. There are about 90 million hepatitis B carriers in China, including about 20 million chronic hepatitis B carriers. Every year, about 2%-5% of compensated cirrhosis patients progress to decompensated cirrhosis patients. Studies have shown that the 5-year survival rate of decompensated liver cirrhosis is only 14-35%, and the quality of life and prognosis of patients are poor. From the progression of liver fibrosis to the decompensation of liver cirrhosis, liver failure often occurs. Statistics show that slow increase The 28-day mortality rate of patients with acute liver failure of grade 1, 2 and 3 is as high as 22%, 32% and 77%. The 90-day mortality rate was 41%, 73%, 95%. Orthotopic liver transplantation is the most effective means to treat decompensated liver failure due to liver cirrhosis, However, the shortage of donor liver, immune rejection and high cost have become treatment obstacles. Application of artificial liver support system for blood flow Plasma replacement can remove toxic substances from blood, but it can't supplement albumin and coagulation factors, and it is important to whether reducing the mortality rate is still controversial. Therefore, it reverses or delays the process of liver cirrhosis and reduces the compensatory stage of liver cirrhosis It is an important link in the treatment of liver diseases that the patients develop into decompensated stage The curative effect of medical treatment on hepatitis B cirrhosis (compensatory period) is very limited; Liver transplantation is difficult to popularize in clinical application due to the lack of donors and high cost. Mesenchymal Stem Cells (MSCs) are derived from mesoderm in early development, is a high degree of self-renewal ability, Pluripotent stem cells with high proliferation ability and multidirectional differentiation potential widely exist in bone marrow, fat, umbilical cord blood, umbilical cord, and other tissues. They can be cultured and expanded in vitro, and can differentiate into adipocytes, osteoblasts, cartilage tissues, nerve cells, hepatocytes and so on under the control of specific conditions, which has great application value in cell therapy and tissue engineering. The purpose of this study was to investigate the efficacy and safety of umbilical cord mesenchymal stem cells in the treatment of hepatitis B cirrhosis (compensatory stage). The subjects were randomly divided into two groups: umbilical cord mesenchymal stem cells injected through peripheral vein group and control group, with 10 cases in each group, a total of 20 cases. The subjects were randomly divided into two groups, namely, umbilical cord mesenchymal stem cells injected through peripheral vein group and control group. Patients in the treatment group were treated with stem cells based on conventional medical treatment. The efficacy and adverse reactions of patients were observed in detail within 24 weeks after treatment, and the long-term effect of stem cell therapy was observed after 96 weeks of treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental MSCs Participants will receive antiviral drug, anti-fibrotic drugs and UC-MSCs |
Biological: UC-MSCs
Usage: The stem cell preparation in this study is used intravenously in the elbow.
Dose: The dose of stem cell injection in this clinical study is set at 1×10^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
|
| Placebo Comparator: Comparator Comparator participants will receive antiviral drug, anti-fibrotic drugs and saline solution |
Biological: Saline solution
Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
|
Outcome Measures
Primary Outcome Measures
- FibroScan [Change from Baseline Liver stiffness at week 24]
Parameters of liver stiffness
- IV-C [Change from Baseline at week 24]
Change of Serum hepatic fibrosis indexes
- HA [Change from Baseline at week 24]
Change of Serum hepatic fibrosis indexes
- LN [Change from Baseline at week 24]
Change of Serum hepatic fibrosis indexes
- PC-III [Change from Baseline at week 24]
Change of Serum hepatic fibrosis indexes
- Hepatic histopathologic examination [Change from Baseline at week 24]
Status of the liver
- IgG [Change from Baseline at week 24]
Change of humoral immunity
- IgA [Change from Baseline at week 24]
Change of humoral immunity
- IgM [Change from Baseline at week 24]
Change of humoral immunity
- IgE [Change from Baseline at week 24]
Change of humoral immunity
- C3 [Change from Baseline at week 24]
Change of humoral immunity
- C4 [Change from Baseline at week 24]
Change of humoral immunity
- CD3 [Change from Baseline at week 24]
Change of cellular immunity
- CD4 [Change from Baseline at week 24]
Change of cellular immunity
- CD8 [Change from Baseline at week 24]
Change of cellular immunity
- CD19 [Change from Baseline at week 24]
Change of cellular immunity
- CD16+56 [Change from Baseline at week 24]
Change of cellular immunity
Secondary Outcome Measures
- ALB [Change from Baseline at week 24]
Change of Liver function
- ALT [Change from Baseline at week 24]
Change of Liver function
- AST [Change from Baseline at week 24]
Change of Liver function
- TBIL [Change from Baseline at week 24]
Change of Liver function
- DBIL [Change from Baseline at week 24]
Change of Liver function
- HBV-DNA [Change from Baseline at week 24]
Status of HBV infection
- Change of ultrasound examination of liver [Change from Baseline at week 24]
Status of the liver
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The age is between 18 and 65 years old (including 18 and 65 years old), regardless of gender;
-
The hardness of liver was detected by transient elastography, and liver cells were detected by imaging and laboratory examination There were no severe complications such as esophageal varices bleeding, ascites, or hepatic encephalopathy;
-
Plasma albumin ≥ 35g / L, total bilirubin < 35μThe activity of prothrombin was more than 60%, The child Pugh score was Grade A;
-
Willing to participate in this clinical study, will cooperate with doctors to carry out research, and sign informed consent.
Exclusion Criteria:
-
Spontaneous peritonitis or other severe infections were found;
-
Patients with hepatorenal syndrome;
-
Severe hepatic encephalopathy, massive hemorrhage of digestive tract or variceal hemorrhage occurred;
-
Combined with serious heart, lung, kidney, blood, endocrine system diseases; There were portal vein thrombosis;
-
Patients with positive serum HIV antibody;
-
The etiology of liver cirrhosis is not chronic HBV infection (HCV, EBV, CMC, autoimmune liver disease, primary biliary cirrhosis, parasitic, alcoholic, drug-related, genetic metabolic, genetic metabolic diseases), or other factors besides chronic HBV infection;
-
Malignant tumor of liver or other organs;
-
Pregnant women, lactating women, or those with recent birth planning;
-
Those who have a history of alcoholism and drug abuse and fail to give up effectively;
-
Participated in other clinical trials within 3 months before enrollment;
-
Participated in stem cell clinical research before;
-
Not willing to sign informed consent form;
-
Those who have neurological or mental disorders and are unable to cooperate or are unwilling to cooperate;
-
Other situations in which the researcher considered that the patient should not participate in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Renmin Hospital of Wuhan University | Wuhan | Hubei | China |
Sponsors and Collaborators
- Renmin Hospital of Wuhan University
- VCANBIO Cell & Gene Engineering Corporation, Ltd
- Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China
Investigators
- Principal Investigator: YINGAN JIANG, Renmin Hospital of Wuhan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RenminHJiangYingan